Serum thymosin alpha 1 levels in normal and pathological conditions

References

• Low TLK, Thurman GB, McAdoo M, et al. The chemistry and biology of thymosin. I. Isolation, characterization and biological activities of thymosin alpha1 and polypeptide beta1 from calf thymus. J Biol Chem. 1979;254:981–986.
   PubMed Web of Science ®Google Scholar
• Low TLK, Goldstein AL. The chemistry and biology of thymosin. II. Amino acid sequence analysis of thymosin alpha1 and polypeptide beta1. J Biol Chem. 1979;254:987–995.
   PubMed Web of Science ®Google Scholar
• Sarandeses CS, Covelo G, D_ıaz-Jullien C, et al. Prothymosin alpha is processed to thymosin alpha 1 and thymosin alpha 11 by a lysosomal asparaginyl endopeptidase. J Biol Chem. 2003;278:13286–13293.
   PubMed Web of Science ®Google Scholar
• Franco FJ, Diaz C, Barcia M, et al. Thymosin alpha 1 is a native peptide in several tissues. Biochim Biophys Acta. 1992;1120:43–48.
   PubMed Web of Science ®Google Scholar
• Garaci E, Favalli C, Pica F, et al. Thymosin alpha 1: from bench to bedside. Ann NY Acad Sci. 2007;1112:225–234.
   PubMed Web of Science ®Google Scholar
• Yao Q, Doan LX, Zhang R, et al. Thymosin alpha1 modulates dendritic cell differentiation and functional maturation from human peripheral blood CD14+ monocytes. Immunol Lett. 2007;110:110–120.
   PubMed Web of Science ®Google Scholar
• Zhang P, Chan J, Dragoi AM, et al. Activation of IKK by thymosin alpha1 requires the TRAF6 signaling pathway. EMBO Rep. 2005;6:531–537.
   PubMed Web of Science ®Google Scholar
• Romani L, Bistoni F, Gaziano R, et al. Thymosin alpha1 activates dendritic cells for antifungal Th1 resistance through toll-like receptor signaling. Blood. 2004;103:4232–4239.
   PubMed Web of Science ®Google Scholar
• Romani L, Bistoni F, Perruccio K, et al. Thymosin alpha1 activates dendritic cell tryptophan catabolism and establishes a regulatory environment for balance of inflammation and tolerance. Blood. 2006;108:2265–2274.
   PubMed Web of Science ®Google Scholar
• Romani L, Bistoni F, Montagnoli C, et al. Thymosin alpha1: an endogenous regulator of inflammation, immunity, and tolerance. Ann NY Acad Sci. 2007;1112:326–338.
   PubMed Web of Science ®Google Scholar
• Bonifazi P, D’angelo C, Fallarino F, et al. Thymosin alpha1: the regulator of regulators? Ann N Y Acad Sci. 2010;1194:1–5.
   PubMed Web of Science ®Google Scholar
• Umeda Y, Sakamoto A, Nakamura J, et al. Thymosin alpha 1 restores NK-cell activity and prevents tumor progression in mice immunosuppressed by cytostatics or X-rays. Cancer Immunol Immunother. 1983;15:78–83.
   PubMed Web of Science ®Google Scholar
• Di Francesco P, Pica F, Gaziano R, et al. In vivo recovery of natural killer cell activity by the association of thymosin alpha 1 and cytokines during cocaine administration. Med Sci Res. 1994;22:41–42.
   Google Scholar
• Favalli C, Jezzi T, Mastino A, et al. Modulation of natural killer activity by thymosin alpha 1 and interferon. Cancer Immunol Immunother. 1985;20:189–192.
   PubMed Web of Science ®Google Scholar
• Serrate SA, Schulof RS, Leondaridis L, et al. Modulation of human natural killer cell cytotoxic activity, limphokine production, and interleukine-2 receptor expression by thymic hormones. J Immunol. 1987;139:2338–2343.
   PubMed Web of Science ®Google Scholar
• Mastino A, Favalli C, Grelli S, et al. Combination therapy with thymosin alpha 1 potentiates the anti-tumor activity of interleukin-2 with cyclophosphamide in the treatment of Lewis lung carcinoma in mice. Int J Cancer. 1990;50:493–499.
   Web of Science ®Google Scholar
• Garaci E, Mastino A, Pica F, et al. Combination treatment using thymosin alpha 1 and interferon after cyclophosphamide is able to cure Lewis lung carcinoma in mice. Cancer Immunol Immunother. 1990;32:154–160.
   PubMed Web of Science ®Google Scholar
• Rasi G, Silecchia G, Sinibaldi-Vallebona P, et al. Anti-tumor effect of combined treatment with thymosin alpha 1 and interleukin-2 after 5-fluorouracil in liver metastases from colorectal cancer in rats. Int J Cancer. 1994;57:701–705.
   PubMed Web of Science ®Google Scholar
• Silecchia G, Guarino E, Sinibaldi-Vallebona P, et al. Efficacy of repeated cycles of chemo-immunotherapy with thymosin alpha 1 and interleukin-2 after intraperitoneal 5-fluorouracil delivery. Cancer Immunol Immunother. 1999;48:172–178.
   PubMed Web of Science ®Google Scholar
• Garaci E, Rocchi G, Perroni L, et al. Combination treatment with zidovudine, thymosin alpha 1 and interferon alpha in human immunodeficiency virus infection. Int J Clin Lab Res. 1994;24:23–28.
   PubMedGoogle Scholar
• Pica F, Fraschetti M, Matteucci C, et al. High doses of thymosin alpha 1 enhance the anti-tumor efficacy of combination chemo-immunotherapy for murine B16 melanoma. Anticancer Res. 1998;18:3571–3578.
   PubMed Web of Science ®Google Scholar
• Romani L, Moretti S, Fallarino F, et al. Jack of all trades: thymosin alpha 1 and its pleiotropy. Ann N Y Acad Sci. 2012;1269:1–6.
   PubMed Web of Science ®Google Scholar
• Shrivastava P, Singh SM, Singh N. Effect of thymosin alpha 1 on the antitumor activity of tumor-associated macrophage derived dendritic cells. J Biomed Sci. 2004;11:623–630.
   PubMed Web of Science ®Google Scholar
• Peng Y, Chen Z, Yu W, et al. Effects of thymic polypeptides on the thymopoiesis of mouse embryonic stem cells. Cell Biol Int. 2008;32:1265–1271.
   PubMed Web of Science ®Google Scholar
• Loggi E, Gramenzi A, Margotti M, et al. In vitro effect of thymosin alpha 1 and interferon alpha on Th1 and Th2 cytokine synthesis in patients with eAg negative chronic hepatitis B. J Viral Hepat. 2008;15:442–448.
   PubMed Web of Science ®Google Scholar
• Sztein MB, Serrate SA, Goldstein AL. Modulation of interleukin-2 receptor expression on normal human lymphocytes by thymic hormones. Proc Natl Acad Sci USA. 1986;83:6107–6111.
   PubMed Web of Science ®Google Scholar
• Sztein MB, Serrate SA. Characterization of the immunoregulatory properties of thymosin alpha 1 on interleukin-2 production and interleukin-2 receptor expression in normal human lymphocytes. Int J Immunopharmacol. 1989;11:789–800.
   PubMed Web of Science ®Google Scholar
• Leichtling KD, Serrate SA, Sztein MB. Thymosin alpha 1 modulates the expression of high affinity interleukin-2 receptors on normal human lymphocytes. Int J Immunopharmacol. 1990;12:19–29.
   PubMed Web of Science ®Google Scholar
• Hsia J, Sarin N, Oliver JH, et al. Aspirin and thymosin increase interleukin-2 and interferon gamma production by human peripheral blood lymphocytes. Immunopharmacology. 1989;17:167–173.
   PubMed Web of Science ®Google Scholar
• Garaci E, Pica F, Serafino A, et al. Thymosin α1 and cancer: action on immune effector and tumor target cells. Ann N Y Acad Sci. 2012 Oct;1269:26–33.
   PubMed Web of Science ®Google Scholar
• Garaci E, Pica F, Matteucci C, et al. Historical review on thymosin α1 in oncology: preclinical and clinical experiences. Expert Opin Biol Ther. 2015;15(Suppl 1):S31–S39.
   PubMed Web of Science ®Google Scholar
• Giuliani C, Napolitano G, Mastino A, et al. Thymosin alpha 1 regulates MHC class I expression in FRTL-5 cells at transcriptional level. Eur J Immunol. 2000;30:778–786.
   PubMed Web of Science ®Google Scholar
• Palamara A, Bue M, Savini P, et al. Thymosin alpha 1 inhibits Sendai virus replication: involvement of intracellular redox state. 6th International Expert Forum of Immunotherapy and Gene Therapy, Florence, Italy; 1998
   Google Scholar
• Moody TW, Fagarasan M, Zia F, et al. Thymosin alpha 1 down-regulates the growth of human non-small cell lung cancer cells in vitro and in vivo. Cancer Res. 1993;53:5214–5218.
   PubMed Web of Science ®Google Scholar
• Nepravishta R, Mandaliti W, Eliseo T, et al. Thymosin a1 inserts N terminus into model membranes assuming a helical conformation. Expert Opin Biol Ther. 2015;15:S71–81.
   PubMed Web of Science ®Google Scholar
• Mandaliti W, Nepravishta R, Sinibaldi Vallebona P, et al. Thymosin a1 interacts with exposed phosphatidylserine in membrane models and in cells and uses serum albumin as carrier. Biochemistry. 2016;55:1462–1472.
   PubMed Web of Science ®Google Scholar
• Mandaliti W, Nepravishta R, Pica F, et al. Thymosin α1 interacts with hyaluronic acid electrostatically by its terminal sequence LKEKK. Molecules. 2017 Oct 27;22(11):E1843.
   PubMed Web of Science ®Google Scholar
• Goldstein AL, Goldstein AL. From lab to bedside: emerging clinical applications of thymosin alpha 1. Expert Opin Biol Ther. 2009;9:593–608.
   PubMed Web of Science ®Google Scholar
• Tuthill C, Rios I, De Rosa A, et al. Thymosin α1 continues to show promise as an enhancer for vaccine response. Ann N Y Acad Sci. 2012 Oct;1270:21–27.
   PubMed Web of Science ®Google Scholar
• Tuthill CW, King RS. Thymosin alpha 1 – a peptide immune modulator with a broad range of clinical applications. Clin Exp Pharmacol. 2013;3:133.
   Google Scholar
• Camerini R, Garaci E. Historical review of thymosin α 1 in infectious diseases. Expert Opin Biol Ther. 2015;15(Suppl 1):S117–S127.
   PubMedGoogle Scholar
• Qiu SJ, Zhou ZG, Shen F, et al. A multicenter, randomized, observation-controlled clinical trial to evaluate the efficacy and safety of thymalfasin adjuvant therapy in patients with HBV-related HCC after curative resection - first announcement of the protocol. Expert Opin Biol Ther. 2015;15(Suppl 1):S133–S137.
   PubMedGoogle Scholar
• Wu X, Jia J, You H. Thymosin alpha-1 treatment in chronic hepatitis B. Expert Opin Biol Ther. 2015;15(Suppl 1):S129–S132.
   PubMedGoogle Scholar
• Ciancio A, Andreone P, Kaiser S, et al. Thymosin alpha-1 with peginterferon alfa-2a/ribavirin for chronic hepatitis C not responsive to IFN/ribavirin: an adjuvant role? J Viral Hepat. 2012 Jan;19(Suppl 1):52–59.
   PubMedGoogle Scholar
• Liu F, Wang HM, Wang T, et al. The efficacy of thymosin α1 as immunomodulatory treatment for sepsis: a systematic review of randomized controlled trials. BMC Infect Dis. 2016 Sep 15;16:488.
   PubMed Web of Science ®Google Scholar
• Wang FY, Fang B, Qiang XH, et al. The efficacy and immunomodulatory effects of ulinastatin and thymosin α1 for sepsis: a systematic review and meta-analysis. Biomed Res Int. 2016;2016:9508493.
   PubMedGoogle Scholar
• Wu J, Zhou L, Liu J, et al. The efficacy of thymosin alpha 1 for severe sepsis (ETASS): a multicenter, single-blind, randomized and controlled trial. Crit Care. 2013 Jan 17;17(1):R8.
   PubMed Web of Science ®Google Scholar
• Wang X, Li W, Niu C, et al. Thymosin alpha 1 is associated with improved cellular immunity and reduced infection rate in severe acute pancreatitis patients in a double-blind randomized control study. Inflammation. 2011 Jun;34(3):198–202.
   PubMed Web of Science ®Google Scholar
• Jia Z, Feng Z, Tian R, et al. Thymosin α1 plus routine treatment inhibit inflammatory reaction and improve the quality of life in AECOPD patients. Immunopharmacol Immunotoxicol. 2015;37(4):388–392.
   PubMed Web of Science ®Google Scholar
• Wara DW, Goldstein AL, Doyle NE, et al. Thymosin activity in patients with cellular immunodeficiency. N Engl J Med. 1975 Jan 9; 292(2):70–74.
   PubMed Web of Science ®Google Scholar
• Goldstein AL. History of the discovery of the thymosins. Ann N Y Acad Sci. 2007 Sep;1112:1–13. Epub 2007 Jun 28.
   PubMed Web of Science ®Google Scholar
• White A, Goldstein AL. The endocrine role of the thymus and its hormone, thymosin, in the regulation of the growth and maturation of host immunological competence. Adv Metab Disord. 1975;8:359–374.
   PubMedGoogle Scholar
• Chretien PB, Lipson SD, Makuch R, et al. Thymosin in cancer patients: in vitro effects and correlations with clinical response to thymosin immunotherapy. Cancer Treat Rep. 1978;62(11):1787–1790.
   PubMedGoogle Scholar
• Schulof RS, Lloyd MJ, Cleary PA, et al. A randomized trial to evaluate the immunorestorative properties of synthetic thymosin-alpha 1 in patients with lung cancer. J Biol Response Mod. 1985;4:147–158.
   PubMedGoogle Scholar
• Lopez M, Carpano S, Cavaliere R, et al. Biochemotherapy with thymosin alpha 1, interleukin-2 and dacarbazine in patients with metastatic melanoma: clinical and immunological effects. Ann Oncol. 1994;5(8):741–766.
   PubMed Web of Science ®Google Scholar
• Rasi G, Terzoli E, Izzo F, et al. Combined treatment with thymosin alpha 1 and low-dose interferon alpha after dacarbazine in advanced melanoma. Melanoma Res. 2000;10:189–192.
   PubMed Web of Science ®Google Scholar
• Maio M, Mackiewicz A, Testori A, et al. Large randomized study of thymosin alpha 1, interferon alfa, or both in combination with dacarbazine in patients with metastatic melanoma. J Clin Oncol. 2010;28(10):1780–1787.
   PubMed Web of Science ®Google Scholar
• Garaci E, Lopez M, Bonsignore G, et al. Sequential chemoimmunotherapy for advanced non-small cell lung cancer using cisplatin, etoposide, thymosin-alpha 1 and interferon-alpha 2a. Eur J Cancer. 1995;31A(13–14):2403–2405.
   PubMed Web of Science ®Google Scholar
• Salvati F, Rasi G, Portalone L, et al. Combined treatment with thymosin alpha 1 and low-dose interferon-alpha after ifosfamide in non-small cell lung cancer: a phase II controlled trial. Anticancer Res. 1996;16:1001–1004.
   PubMed Web of Science ®Google Scholar
• Wolf E, Milazzo S, Boehm K, et al. Thymic peptides for treatment of cancer patients. Cochrane Database Syst Rev. 2011;(2):CD003993.
   PubMed Web of Science ®Google Scholar
• Sherman KE, Jones CC, Goldstein AL, et al. Low thymosin alpha-1 concentrations in patients chronically infected with the hepatitis B virus. Viral Immunol. 1991;4(3):195–199. Fall.
   PubMedGoogle Scholar
• Mutchnick MG, Appelman HD, Chung HT, et al. Thymosin treatment of chronic hepatitis B: a placebo-controlled pilot trial. Hepatology. 1991 Sep;14(3):409–415.
   PubMed Web of Science ®Google Scholar
• Rasi G, Mutchnick MG, Di Virgilio D, et al. Combination low-dose lymphoblastoid interferon and thymosin alpha 1 therapy in the treatment of chronic hepatitis B. J Viral Hepat. 1996 Jul;3(4):191–196.
   PubMed Web of Science ®Google Scholar
• Rasi G, DiVirgilio D, Mutchnick MG, et al. Combination thymosin alpha 1 and lymphoblastoid interferon treatment in chronic hepatitis C. Gut. 1996 Nov;39(5):679–683.
   PubMed Web of Science ®Google Scholar
• Rasi G, Pierimarchi P, Sinibaldi Vallebona P, et al. Combination therapy in the treatment of chronic viral hepatitis and prevention of hepatocellular carcinoma. Int Immunopharmacol. 2003 Aug;3(8):1169–1176.
   PubMed Web of Science ®Google Scholar
• Naylor PH, Mutchnick MG. Immunotherapy for hepatitis B in the direct acting antiviral era: reevaluating the thymosin α1 efficacy trials in the light of a combination therapy approach. J Viral Hepat. 2018 Jan;25(1):4–9.
   PubMed Web of Science ®Google Scholar
• Giacomini E, Rizzo F, Etna MP, et al. Thymosin-α1 expands deficient IL-10-producing regulatory B cell subsets in relapsing-remitting multiple sclerosis patients. Mult Scler. 2017 Feb;1:1352458517695892.
   Google Scholar
• Romani L, Oikonomou V, Moretti S, et al. Thymosin α1 represents a potential potent single-molecule-based therapy for cystic fibrosis. Nat Med. 2017 May;23(5):590–600.
   PubMed Web of Science ®Google Scholar
• McClure JE, Lameris N, Wara DW, et al. Immunochemical studies on thymosin: radioimmunoassay of thymosin et. J Lmmun. 1982;128(368):375.
   Google Scholar
• Hirokawa D, Saitoh K 1980 Heterogeneity of thymic epithelial cells revealed by the localization of thymosin α 1 and various hydrolytic enzyme in human thymus. 4th international congress immunology, p.3.3.14 (Abstract)
   Google Scholar
• Naylor PH, Friedman-Kien A, Hersh E, et al. Thymosin α 1 and thymosin β 4 in serum: comparison of normal, cord, homosexual and AIDS serum. Int J Immunopharmac. 1986;8:667–676.
   PubMed Web of Science ®Google Scholar
• Chen SJ, Ko HS. Serum thymosin-alpha 1: lack of association between elevated levels and HIV infection. Clin Exp Immunol. 1987 Nov;70(2):263–267.
   PubMed Web of Science ®Google Scholar
• Wada S, Naylor PH, Naylor CW, et al. Improved ELISA to measure thymosin alpha 1: comparison of whole and absorbed antisera. Int J Immunopharmacol. 1988;10(7):795–801.
   PubMed Web of Science ®Google Scholar
• Naylor PH, Naylor CW, Sasaki D, et al. Utilization of HPLC-ELISA to assess serum levels of thymosin α 1 following subcutaneous administration to human subjects. J Liquid Chromatogr. 1994;17:3541–3551.
   Web of Science ®Google Scholar
• Tuthill CW, Rudolph A, Li Y, et al. Quantitative analysis of thymosin alpha1 in human serum by LC-MS/MS. AAPS PharmSciTech. 2000 May 14;1(2):E11.
   PubMedGoogle Scholar
• Schulof R, Lloyd JJ, Cox J, et al. An evaluation of two different schedules of synthetic thymosin alpha 1 administration in patients with lung cancer. Preliminary results. In: Goldstein AL, Ed. Thymic hormones and lymphokines. New York: Plenum Press; 1984. p. 601–613.
   Google Scholar
• Wills RJ. Clinical pharmacokinetics of interferons. Clin Pharmacokinet. 1990 Nov;19(5):390–399.
   PubMed Web of Science ®Google Scholar
• Badamchian M, Mora CA, Baumann CA, et al. Biodistribution of synthetic thymosin alpha1 in the serum, urine and major organs of mice. Int J Immunopharmacol. 1997 Feb;19(2):59–66.
   PubMed Web of Science ®Google Scholar
• Liaw Y-F. Current therapeutic trends in therapy for chronic viral hepatitis. J Gastroenterol Hepatol. 1997;12(suppl):S346–S353.
   PubMedGoogle Scholar
• Rost KL, Wierich W, Masayuki F, et al. Pharmacokinetics of thymosin α1 after subcutaneous injection of three different formulations in healthy volunteers. Int J Clin Pharmacol Ther. 1999;37(1):51–57.
   PubMed Web of Science ®Google Scholar
• Ancell CD, Phipps J, Young L. Thymosin alpha-1. Am J Health Syst Pharm. 2001 May 15; 58(10):879–85;quiz 886–8. Review.
   PubMed Web of Science ®Google Scholar
• Pica F, Chimenti MS, Gaziano R, et al. Serum thymosin α 1 levels in patients with chronic inflammatory autoimmune diseases. Clin Exp Immunol. 2016 Oct;186(1):39–45.
   PubMed Web of Science ®Google Scholar
• Serafino A, Pierimarchi P, Pica F, et al. Thymosin a1 as a stimulatory agent of innate cell-mediated immune response. Ann NY Acad Sci. 2012;1270:13–20.
   PubMed Web of Science ®Google Scholar
• Torcia MG, Nencioni L, Clemente AM, et al. Sex differences in the response to viral infections: TLR8 and TLR9 ligand stimulation induce higher IL 10 production in males. PlosONE. 2012;7:e39853.
   PubMed Web of Science ®Google Scholar
• Libert C, Dejager L, Pinheiro I. The X chromosome in immune functions: when a chromosome makes the difference. Nat Rev Immunol. 2010;10:594–604.
   PubMed Web of Science ®Google Scholar
• Quintero OL, Amador-Patarroyo MJ, Montoya-Ortiz G, et al. Autoimmune disease and gender: plausible mechanisms for the female predominance of autoimmunity. J Autoimmun. 2012;38:J109–19.
   PubMed Web of Science ®Google Scholar
• Veale DJ, Fearon U. What makes psoriatic and rheumatoid arthritis so different? RMD Open. 2015;1:e000025.
   PubMed Web of Science ®Google Scholar
• Conigliaro P, Triggianese P, Perricone C, et al. Restoration of peripheral blood natural killer and B cell levels in patients affected by rheumatoid and psoriatic arthritis during Etanercept treatment. Clin Exp Immunol. 2014;177:234–243.
   PubMed Web of Science ®Google Scholar
• Jou YC, Tsai YS, Hsieh HY, et al. Plasma thymosin-a1 level as a potential biomarker in urothelial and renal cell carcinoma. Urol Oncol. 2013;31:1806–1811.
   PubMed Web of Science ®Google Scholar
• Sasaki H, Fujii Y, Masaoka A, et al. Elevated plasma thymosin-alpha1 levels in lung cancer patients. Eur J Cardiothorac Surg. 1997 Dec;12(6):885–891.
   PubMed Web of Science ®Google Scholar
• Mitani M, Kuwabara Y, Kawamura H, et al. Significance of plasma thymosin alpha1 measurements in gastric cancer patients. World J Surg. 2000 Apr;24(4):455–458.
   PubMed Web of Science ®Google Scholar
• Angus DC, Linde-Zwirble WT, Lidicker J, et al. Epidemiology of severe sepsis in the United States: analysis of incidence, outcome, and associated costs of care. Crit Care Med. 2001;29:1303–13010.
   PubMed Web of Science ®Google Scholar
• Hotchkiss RS, Karl IE. The pathophysiology and treatment of sepsis. N Engl J Med. 2013;348:138–150.
   Google Scholar
• Ryan T, Coakley JD, Martin-Loeches I. Defects in innate and adaptive immunity in patients with sepsis and health care associated infection. Ann Transl Med. 2017 Nov;5(22):447.
   PubMed Web of Science ®Google Scholar
• Payen D, Monneret G, Hotchkiss R. Immunotherapy - a potential new way forward in the treatment of sepsis. Crit Care. 2013 Feb 20;17(1):118.
   PubMed Web of Science ®Google Scholar
• McGillis JP, Hall NR, Goldstein AL. Circadian rhythm of thymosin-alpha 1 in normal and thymectomized mice. J Immunol. 1983 Jul;131(1):148–151.
   PubMed Web of Science ®Google Scholar
• Molinero P, Soutto M, Benot S, et al. Melatonin is responsible for the nocturnal increase observed in serum and thymus of thymosin alpha1 and thymulin concentrations: observations in rats and humans. J Neuroimmunol. 2000;103:180–188.
   PubMed Web of Science ®Google Scholar